Igrene (ABI) Q4 2025 earnings summary

Executive summary

• Focus on converting biogenic methane from Siljansringen into hydrogen and carbon using SEID AS's cold pyrolysis technology, with EU support and significant innovation awards.

• Strategic aim to commercialize green hydrogen and carbon, reducing methane emissions and providing sought-after raw materials for battery and graphene production.

• Demonstration plant plans delayed due to regulatory hurdles; alternative locations under review.

Financial highlights

• Revenue for the period was 0 KSEK, down from 255 KSEK year-over-year.

• Operating loss widened to -8,534 KSEK from -5,204 KSEK year-over-year.

• Net loss after financial items was -8,396 KSEK, compared to -5,202 KSEK the previous year.

• Earnings per share improved to -0.08 SEK from -0.10 SEK year-over-year.

• Cash and cash equivalents at period end were 1,912 KSEK, up from 972 KSEK.

Outlook and guidance

• No dividend proposed for 2024/2025.

• Focus remains on securing permits and alternative sites for demonstration plant and scaling up production.